CCR4 Antagonists Inhibit Treg Trafficking into the Tumor Microenvironment
Authors:
- 10 September 2018
- journal article
- editorial
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 9 (10) , 953-955
Abstract
Recruitment of naturally occurring suppressive CD4+, CD25+, and FOXP3+ regulatory T cells (Treg) to the tumor microenvironment (TME) has the potential to weaken the antitumor response in patients receiving treatment with immuno-oncology (IO) agents. Human Treg express CCR4 and can be recruited to the TME through the C–C chemokines CCL17 and CCL22. We have recently developed a series of potent, orally bioavailable small molecule antagonists of CCR4 that can block recruitment of Treg into the TME.Keywords
This publication has 9 references indexed in Scilit:
- Small molecule immuno-oncology therapeutic agentsBioorganic & Medicinal Chemistry Letters, 2018
- Discovery of AZD-2098 and AZD-1678, Two Potent and Bioavailable CCR4 Receptor AntagonistsACS Medicinal Chemistry Letters, 2017
- Introduction to checkpoint inhibitors and cancer immunotherapyImmunological Reviews, 2017
- Targeting chemokine receptors in disease – a case study of CCR4European Journal of Pharmacology, 2015
- Internalization of the chemokine receptor CCR4 can be evoked by orthosteric and allosteric receptor antagonistsEuropean Journal of Pharmacology, 2014
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humansProceedings of the National Academy of Sciences, 2013
- Safety, tolerability, pharmacokinetics and pharmacodynamics of GSK2239633, a CC-chemokine receptor 4 antagonist, in healthy male subjects: results from an open-label and from a randomised studyBMC Pharmacology and Toxicology, 2013
- Regulatory T cells in tumor immunityInternational Journal of Cancer, 2010
- CCR4 as a novel molecular target for immunotherapy of cancerCancer Science, 2006